Skip to main content

Table 2 Impact of patient characteristics and treatment on hematuria incidence within three years post-SBRT

From: Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

Factors Univariate analysis Multivariate analysis
Age 0.651 0.419
Race 0.523 0.917
D’Amico’s Risk Groups 0.805 0.122
Prostate Volume 0.022† 0.081
Initial PSA 0.546 0.804
Androgen Deprivation Therapy 0.507 0.507
Procedure for BPH prior to RT 0.002† <0.0001*
Initial AUA 0.508 0.897
α 1A Antagonist usage 0.082 0.008*
Charlson Comorbidity Index 0.787 0.101
Anticoagulant usage 0.321 0.435
  1. significant in univariate analysis, *significant in multivarariate analysis.